Lionel Groussin Selected Research

Cyclic AMP (AMP, Cyclic)

9/2009	Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells.
6/2008	Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
11/2006	Mechanisms of disease: adrenocortical tumors--molecular advances and clinical perspectives.
7/2006	A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia.
1/2005	Adrenal pathophysiology: lessons from the Carney complex.
11/2002	cAMP pathway alterations from the cell surface to the nucleus in adrenocortical tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lionel Groussin Research Topics

Disease

35	Neoplasms (Cancer) 08/2022 - 05/2002
23	Cushing Syndrome 08/2022 - 05/2002
13	Hyperplasia 05/2022 - 05/2002
10	Adrenocortical Carcinoma 04/2022 - 08/2003
9	Adenoma (Adenomas) 06/2022 - 05/2002
9	Thyroid Neoplasms (Thyroid Cancer) 01/2022 - 08/2013
8	Acth-Independent Macronodular Adrenal Hyperplasia 11/2013 - 05/2002
7	Carney Complex 01/2011 - 12/2002
6	Adrenocortical Adenoma (Disease, Conn's) 01/2021 - 08/2003
6	Carcinogenesis 09/2009 - 12/2002
6	Adrenal Cortex Neoplasms (Adrenocortical Cancer) 10/2008 - 11/2002
4	Primary Hyperparathyroidism 06/2022 - 11/2020
4	Neoplasm Metastasis (Metastasis) 11/2021 - 06/2004
4	Pituitary ACTH Hypersecretion 01/2012 - 12/2008
3	Disease Progression 01/2022 - 06/2014
3	Papillary Thyroid Cancer 04/2017 - 12/2015
2	Multiple Endocrine Neoplasia Type 1 06/2022 - 10/2018
2	Type 2 Diabetes Mellitus (MODY) 01/2020 - 01/2018
2	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2020 - 01/2018
2	Obesity 01/2020 - 01/2018
2	Hypothyroidism 01/2020 - 06/2017
2	Pseudohypoparathyroidism 01/2020 - 01/2018
2	Adrenal Insufficiency (Adrenal Gland Hypofunction) 06/2017 - 02/2010
2	Thyroiditis 06/2017 - 02/2013
2	Vitamin D Deficiency 12/2016 - 01/2016
2	Chronic Renal Insufficiency 01/2016 - 07/2014
2	Myxoma (Myxomas) 06/2009 - 05/2006
1	Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis) 06/2022
1	Thyrotoxicosis 06/2021
1	Adrenogenital Syndrome 01/2021
1	Adrenal Rest Tumor 01/2021
1	Addison Disease (Addison's Disease) 01/2021
1	Pheochromocytoma 01/2020
1	Brachydactyly 01/2020
1	Paraganglioma (Paragangliomas) 01/2020
1	Parathyroid Neoplasms (Parathyroid Neoplasm) 11/2019
1	Prolactinoma (Prolactinomas) 10/2018
1	Congenital Abnormalities (Deformity) 01/2018
1	Weight Gain 01/2018
1	Glucose Intolerance 01/2018

Drug/Important Bio-Agent (IBA)

19	Hydrocortisone (Cortisol)FDA LinkGeneric 08/2022 - 05/2002
15	Adrenocorticotropic Hormone (ACTH)FDA Link 08/2022 - 05/2002
9	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2002
9	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2011 - 12/2002
6	IodineIBA 01/2022 - 06/2014
6	Cyclic AMP (AMP, Cyclic)IBA 09/2009 - 11/2002
5	SteroidsIBA 08/2022 - 11/2008
5	fluorocholineIBA 06/2022 - 10/2018
5	DNA (Deoxyribonucleic Acid)IBA 07/2020 - 07/2006
5	Biological ProductsIBA 01/2016 - 07/2006
3	AndrogensIBA 08/2022 - 07/2006
3	EnzymesIBA 08/2022 - 01/2021
3	gastric inhibitory polypeptide receptorIBA 01/2022 - 05/2002
3	vandetanib (ZD6474)IBA 11/2021 - 08/2013
3	beta CateninIBA 01/2021 - 09/2005
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2017
3	Vitamin D FDA LinkGeneric 11/2019 - 07/2014
3	CalciumIBA 11/2019 - 01/2016
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2019 - 06/2004
3	Mitotane (Lysodren)FDA Link 01/2017 - 07/2006
3	Phosphorus (Red Phosphorus)IBA 12/2016 - 07/2014
3	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2011 - 07/2006
3	Messenger RNA (mRNA)IBA 05/2008 - 12/2002
3	Carrier Proteins (Binding Protein)IBA 07/2006 - 11/2002
2	OsilodrostatIBA 08/2022 - 05/2021
2	GlucocorticoidsIBA 08/2022 - 10/2009
2	ParaffinIBA 04/2022 - 08/2015
2	larotrectinibIBA 01/2022 - 10/2020
2	Growth Hormone (Somatotropin)IBA 01/2020 - 01/2018
2	Parathyroid Hormone (Parathormone)IBA 01/2020 - 01/2018
2	Phosphotransferases (Kinase)IBA 06/2014 - 05/2008
2	CateninsIBA 02/2011 - 12/2010
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2010 - 01/2003
2	Adenosine (Adenocard)FDA LinkGeneric 10/2008 - 08/2003
2	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 11/2006 - 03/2005
2	ElementsIBA 07/2006 - 08/2003
1	Metyrapone FDA Link 08/2022
1	MineralocorticoidsIBA 08/2022
1	Steroid 11-beta-Hydroxylase (11 beta-Hydroxylase)IBA 08/2022
1	Explosive Agents (Explosives)IBA 08/2022
1	Cytochrome P-450 CYP11B2 (CYP11B2)IBA 08/2022
1	17-alpha-Hydroxyprogesterone (17 Hydroxyprogesterone)IBA 08/2022
1	Cosyntropin (Cortrosyn)FDA LinkGeneric 08/2022
1	LyasesIBA 08/2022
1	cupric sulfide (CuS)IBA 05/2022
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	selpercatinibIBA 10/2021
1	Amiodarone (Amiodarona)FDA LinkGeneric 06/2021
1	Steroid 21-Hydroxylase (21 Hydroxylase)IBA 01/2021
1	Cholesterol Side-Chain Cleavage Enzyme (CYP11A1)IBA 01/2021
1	AldosteroneIBA 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2021
1	lutetium Lu 177 dotatateIBA 01/2020
1	Succinic Acid (Succinate)IBA 01/2020
1	Succinate Dehydrogenase (Fumarate Reductase)IBA 01/2020
1	Circulating Tumor DNAIBA 01/2018

Therapy/Procedure

6	Therapeutics 11/2021 - 09/2005
2	Adrenalectomy 01/2016 - 11/2012
1	Precision Medicine 11/2021
1	Orchiectomy (Orchidectomy) 01/2021